



Supplement 5 Sensorgrams obtained by SPR measurement of the affinity between mAbs having N-glycans with the respective structures shown in Fig. 1 and recombinant human Fc γ RIIIa-V158. (A) mAb having N-glycans with the G1a structure; (B) mAb having N-glycans with the G1aF structure; (C) mAb having N-glycans with the G1b structure; (D) mAb having N-glycans with the G1bF structure; (E) mAb having N-glycans with the G0 structure; (F) mAb having N-glycans with the G0F structure, and (G) untreated mAbs having N-glycans with mixed structures shown in Supplement 2. Recombinant human Fc γ RIIIa-V158 of different concentrations (a, 0.0016; b, 0.008; c, 0.04; d, 0.2 and e, 1.0 μ M, respectively) were injected (∇) at 30 μ l/min to allow interaction with the mAbs for 120 s, followed by injection with plain running buffer (\downarrow) at 30 μ l/min to dissociate the complex for 600 s.